Document Detail


Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used.
MedLine Citation:
PMID:  21939589     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Effects of varenicline (Champix), a nicotinic partial agonist, were evaluated on subjective effects of nicotine (drug discrimination), motivation for nicotine taking (progressive-ratio schedule of intravenous nicotine self-administration) and reinstatement (cue-induced reinstatement of previously extinguished nicotine-seeking behaviour). Effects on motor performance were assessed in rats trained to discriminate nicotine (0.4 mg/kg) from saline under a fixed-ratio (FR 10) schedule of food delivery and in rats trained to respond for food under a progressive-ratio schedule. At short pretreatment times (5-40 min), varenicline produced full or high levels of partial generalization to nicotine's discriminative-stimulus effects and disrupted responding for food, while there were low levels of partial generalization and no disruption of responding for food at 2- or 4-h pretreatment times. Varenicline (1 and 3 mg/kg, 2-h pretreatment time) enhanced discrimination of low doses of nicotine and to a small extent decreased discrimination of the training dose of nicotine. It also dose-dependently decreased nicotine-taking behaviour, but had no effect on food-taking behaviour under progressive-ratio schedules. Finally, varenicline significantly reduced the ability of a nicotine-associated cue to reinstate extinguished nicotine-seeking behaviour. The ability of varenicline to reduce both nicotine-taking and nicotine-seeking behaviour can contribute to its relatively high efficacy in treating human smokers.
Authors:
Bernard Le Foll; Munmun Chakraborty-Chatterjee; Shaul Lev-Ran; Chanel Barnes; Abhiram Pushparaj; Islam Gamaleddin; Yijin Yan; Maram Khaled; Steven R Goldberg
Related Documents :
23332049 - Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascu...
479479 - Acute allergic reaction after composite pollen ingestion.
7583849 - Prevalence of house dust mites in the rocky mountain states.
3409789 - Reducing house-dust mites by vacuuming.
16512809 - Pollen-food syndromes associated with weed pollinosis: an update from the molecular poi...
18489029 - Profilin sensitization detected in the office by skin prick test: a study of prevalence...
8866619 - Stability of microcystins from cyanobacteria--ii. effect of uv light on decomposition a...
21912219 - Gm in the media.
8052579 - Properties of starch and dietary fibre in raw and processed quinoa (chenopodium quinoa,...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2011-09-23
Journal Detail:
Title:  The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)     Volume:  15     ISSN:  1469-5111     ISO Abbreviation:  Int. J. Neuropsychopharmacol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-08-30     Completed Date:  2013-01-17     Revised Date:  2013-10-17    
Medline Journal Info:
Nlm Unique ID:  9815893     Medline TA:  Int J Neuropsychopharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1265-74     Citation Subset:  IM    
Affiliation:
Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Canada. bernard_lefoll@camh.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Benzazepines / pharmacology*
Conditioning, Operant / drug effects
Cues*
Data Interpretation, Statistical
Discrimination (Psychology) / drug effects
Dose-Response Relationship, Drug
Drug-Seeking Behavior / drug effects*
Feeding Behavior / drug effects
Male
Motivation / drug effects
Nicotine / pharmacology
Quinoxalines / pharmacology*
Rats
Rats, Long-Evans
Rats, Sprague-Dawley
Reinforcement Schedule
Self Administration
Tobacco Use Disorder / drug therapy*,  psychology
Grant Support
ID/Acronym/Agency:
Z99 DA999999/DA/NIDA NIH HHS; ZIA DA000003-27/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
0/Benzazepines; 0/Quinoxalines; 54-11-5/Nicotine; W6HS99O8ZO/varenicline
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat front...
Next Document:  Preparing dossiers: strength of the evidence and problems of proof.